Quest distributes Abbott bladder cancer probe:
This article was originally published in Clinica
Executive Summary
Quest Diagnostics has agreed to distribute Abbott Laboratories' bladder cancer probe, Vysis UroVision DNA probe assay, in the US. New labelling claims on the product's effectiveness in monitoring bladder cancer recurrence were cleared by the FDA in March 2002. Vysis UroVision is based on fluorescence in situ hybridisation (FISH) technology, with which cancer cells can be examined while physically intact and are this not destroyed. Quest has been distributing Abbott's FISH-based breast cancer-diagnostic, PathyVision Her-2, since December 2001.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.